# Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 Diabetes

## TL;DR

This review discusses how medications for type 2 diabetes can also treat fatty liver disease, highlighting promising drugs like semaglutide and new treatments in development.

## Contribution

The paper provides an updated overview of pharmacologic treatments for MASLD in T2D, emphasizing recent approvals and emerging therapies.

## Key findings

- GLP-1 RAs, SGLT2 inhibitors, and pioglitazone show benefits for steatohepatitis in T2D patients.
- Semaglutide has the strongest evidence for reducing liver fibrosis.
- New therapies like retatrutide and resmetirom are showing promise in treating MASLD.

## Abstract

Metabolic dysfunction–associated steatotic liver disease (MASLD) is highly prevalent among individuals with type 2 diabetes (T2D). This review summarizes current evidence on the pharmacologic treatment of MASLD, with emphasis on agents currently approved for the management of T2D.

Among glucose-lowering therapies, GLP-1 RAs, dual GIP/GLP-1 RAs, pioglitazone, and SGLT2 inhibitors demonstrate meaningful benefits in steatohepatitis. Semaglutide provides the most robust evidence for fibrosis benefit, while data suggest potential antifibrotic effects of tirzepatide and dapagliflozin. Resmetirom and semaglutide are the only agents specifically approved for MASLD. An expanding pipeline of dual glucagon/GLP-1 and triple GIP/GLP-1/glucagon agonists such as retatrutide has shown marked reductions in liver fat and signals of MASH benefit. Additional therapies, including pan-PPAR agonists, and FGF21 analogues are advancing through phase 3 development.

The therapeutic landscape is rapidly evolving toward integrated metabolic, hepatic, and cardiovascular risk reduction in T2D and MASLD.